# OnCo record laekna-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/laekna-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "laekna-therapeutics" ;
  schema:name "Laekna Therapeutics"@en ;
  schema:alternateName "Laekna"@en, "Laekna Limited"@en, "来凯医药"@en ;
  schema:description "Laekna is a Shanghai drug company listed in Hong Kong. Its lead cancer medicine, afuresertib, taken with fulvestrant for a common type of advanced breast cancer, met its main goal in a phase 3 trial and has been submitted for approval in China. It also works on obesity and liver fibrosis."@en ;
  schema:url <https://onco.cc/companies/laekna-therapeutics/>, <https://www.laekna.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.laekna.com/>, <https://www.laekna.com/rd>, <https://www.laekna.com/aboutus>, <https://clinicaltrials.gov/study/NCT04851613>, <https://www.orbimed.com/portfolio/> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/ovarian/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/cyp17a1/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/afuresertib/>, <https://onco.cc/drugs/lapiteronel/>, <https://onco.cc/drugs/lae118/> ;
  onco:trials <https://onco.cc/trials/nct04851613/> .